Logos Global Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Logos Global Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,250,000	Closed	-$43.3M	–	51
2022 Q1	$43.3M	Buy	1,250,000 +500,000	+67%	+$14.9M	5.61%	6
2021 Q4	$22M	Buy	+750,000	New	+$23.2M	2.26%	16
2020 Q4	–	Sell	-850,000	Closed	-$46.9M	–	69
2020 Q3	$46.9M	Buy	850,000 +715,000	+530%	+$45.4M	6%	5
2020 Q2	$8.52M	Sell	135,000 -50,933	-27%	-$3.49M	1.7%	21
2020 Q1	$9.5M	Buy	+185,933	New	+$12.5M	3.61%	10

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Logos Global Management's GBT Position: Q2 2022 in Review

Logos Global Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2022, closing a stake of 1,250,000 shares — an estimated $43.3M sold.

Logos Global Management first reported a position in GBT in Q1 2020 and held it in 5 quarters. The position peaked at $46.9M in Q3 2020. 195 funds tracked by Wall St. Rank hold GBT as of Q2 2022.

Logos Global Management reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
Logos Global Management sold 1,250,000 Global Blood Therapeutics, Inc. shares in Q2 2022, an estimated $43.3M.
Logos Global Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2020 and held it in 5 quarters.
Logos Global Management's Global Blood Therapeutics, Inc. position peaked at $46.9M in Q3 2020.
195 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2022.

Based on Logos Global Management's 13F filing for Q2 2022, filed 15 Aug 2022.